---
firstreceived_date: February 23, 2012
is_fda_regulated: 
reference: []
overall_contact_backup: {}
completion_date: {}
responsible_party: {}
firstreceived_results_date: 
is_section_801: 
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT01540604
intervention:
- intervention_name: CRD007
  other_name: []
  description: 
  arm_group_label:
  - CRD007 10 mg tablet
  intervention_type: Drug
source: RSPR Pharma AB
eligibility:
  gender: Both
  maximum_age: 11 Years
  sampling_method: 
  minimum_age: 2 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  Documented diagnosis of dystrophinopathy

              Exclusion Criteria:

                -  Severe functional impairment
  healthy_volunteers: 
removed_countries: {}
other_outcome: []
primary_completion_date: {}
last_injected: '2015-07-14T06:45:29.632Z'
intervention_browse: {}
target_duration: 
number_of_arms: '1'
start_date: 
why_stopped: 
id_info:
  org_study_id: Cardoz-004
  secondary_id: []
  nct_alias: []
  nct_id: NCT01540604
acronym: 
arm_group:
- description: 
  arm_group_label: CRD007 10 mg tablet
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: RSPR Pharma AB
    agency_class: Industry
secondary_outcome: []
study_type: Interventional
biospec_retention: 
overall_status: Completed
primary_outcome: []
overall_official:
- first_name: 
  last_name: T Sejersen, MD PhD
  middle_name: 
  affiliation: Karolinska University Hospital
  degrees: 
  role: Principal Investigator
phase: Phase 2
location_countries:
  country:
  - Sweden
condition:
- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy
clinical_results: {}
study_design: N/A
keyword:
- DMD
- BMD
- symptomatic carriers
results_reference: []
oversight_info:
  has_dmc: 
  authority:
  - 'Sweden: Medical Products Agency'
number_of_groups: 
location:
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Stockholm
      state: 
      zip: 
      country: Sweden
  investigator: []
  contact: {}
  geodata:
    latitude: 59.329
    formatted: Stockholm, Sweden
    longitude: 18.065
    original: Stockholm, Sweden
official_title: An Open-label, Un-controlled, Single-centre Trial Investigating the
  Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD)
  or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD
  or BMD
verification_date: October 2012
required_header:
  url: https://clinicaltrials.gov/show/NCT01540604
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact: {}
brief_title: CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular
  Dystrophy and Symptomatic Carriers
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy
          (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
enrollment: {}
lastchanged_date: October 1, 2012
